As Major Insulin Producers Shift Focus, rBIO Steps Up to Address Potential Shortages

rBIO’s biosimilar insulin, R-biolin, achieves bioequivalence to Novo Nordisk Novolin® R in animal studies; company prepares for 50x scale-up and readies for in-human studies HOUSTON, Feb. 4, 2025 /PRNewswire/ — Recent price cuts by major insulin manufacturers may appear to address…